Superior mucoepidermoid carcinoma detection with ⁶⁸Ga-FAPI PET/CT reflects FAP-α expression and MAML2 fusion status
- Sci Rep. 2026 Jan 7;16(1):4410. doi: 10.1038/s41598-025-34528-9.
- 1. Department of Nuclear medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Laboratory for Targeted Radiopharmaceuticals Creation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- 2. Department of Neurology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- 3. Department of Radiology, The Third People's Hospital of Chengdu, Chengdu, 610000, China.
- 4. Department of Neurology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. [email protected].
- 5. Department of Nuclear medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Laboratory for Targeted Radiopharmaceuticals Creation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. [email protected].
This study evaluated the diagnostic potential of the FAP-targeted tracer ⁶⁸Ga-FAPI PET/CT in mucoepidermoid carcinoma (MEC), demonstrating its superior sensitivity over ¹⁸F-FDG PET/CT in detecting primary tumors (100% vs. 85.7%) and metastatic lesions (33 lymph nodes and 19 distant metastases), with significantly higher SUVmax and TBR values. High-grade MEC exhibited elevated stromal FAP-α expression, strongly correlating with ⁶⁸Ga-FAPI uptake metrics (r = 0.91–0.96, p < 0.01), while MAML2-negative tumors showed amplified FAP activity, suggesting stromal activation-driven aggressive behavior. These findings highlight ⁶⁸Ga-FAPI PET/CT as a transformative imaging biomarker for accurate grading, metastasis detection, and risk stratification in MEC, offering a non-invasive stromal imaging paradigm to enhance clinical decision-making and targeted therapy for this histologically complex malignancy.